DOCSLIB.ORG

Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01 A01 STOMATOLOGICAL PREPARATIONS 2.16.840.1.113883.6.73 2017-01 A01A STOMATOLOGICAL PREPARATIONS 2.16.840.1.113883.6.73 2017-01 A01AA Caries prophylactic agents 2.16.840.1.113883.6.73 2017-01 A01AA01 sodium fluoride 2.16.840.1.113883.6.73 2017-01 A01AA02 sodium monofluorophosphate 2.16.840.1.113883.6.73 2017-01 A01AA03 olaflur 2.16.840.1.113883.6.73 2017-01 A01AA04 stannous fluoride 2.16.840.1.113883.6.73 2017-01 A01AA30 combinations 2.16.840.1.113883.6.73 2017-01 A01AA51 sodium fluoride, combinations 2.16.840.1.113883.6.73 2017-01 A01AB Antiinfectives and antiseptics for local oral treatment 2.16.840.1.113883.6.73 2017-01 A01AB02 hydrogen peroxide 2.16.840.1.113883.6.73 2017-01 A01AB03 chlorhexidine 2.16.840.1.113883.6.73 2017-01 A01AB04 amphotericin B 2.16.840.1.113883.6.73 2017-01 A01AB05 polynoxylin 2.16.840.1.113883.6.73 2017-01 A01AB06 domiphen 2.16.840.1.113883.6.73 2017-01 A01AB07 oxyquinoline 2.16.840.1.113883.6.73 2017-01 A01AB08 neomycin 2.16.840.1.113883.6.73 2017-01 A01AB09 miconazole 2.16.840.1.113883.6.73 2017-01 A01AB10 natamycin 2.16.840.1.113883.6.73 2017-01 A01AB11 various 2.16.840.1.113883.6.73 2017-01 A01AB12 hexetidine 2.16.840.1.113883.6.73 2017-01 A01AB13 tetracycline 2.16.840.1.113883.6.73 2017-01 A01AB14 benzoxonium chloride 2.16.840.1.113883.6.73 2017-01 A01AB15 tibezonium iodide 2.16.840.1.113883.6.73 2017-01 A01AB16 mepartricin 2.16.840.1.113883.6.73 2017-01 A01AB17 metronidazole 2.16.840.1.113883.6.73 2017-01 A01AB18 clotrimazole 2.16.840.1.113883.6.73 2017-01 A01AB19 sodium perborate 2.16.840.1.113883.6.73 2017-01 A01AB21 chlortetracycline 2.16.840.1.113883.6.73 2017-01 A01AB22 doxycycline 2.16.840.1.113883.6.73 2017-01 A01AB23 minocycline © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 4 of 490 MTC epSOSActiveIngredient 2.16.840.1.113883.6.73 2017-01 A01AC Corticosteroids for local oral treatment 2.16.840.1.113883.6.73 2017-01 A01AC01 triamcinolone 2.16.840.1.113883.6.73 2017-01 A01AC02 dexamethasone 2.16.840.1.113883.6.73 2017-01 A01AC03 hydrocortisone 2.16.840.1.113883.6.73 2017-01 A01AC54 prednisolone, combinations 2.16.840.1.113883.6.73 2017-01 A01AD Other agents for local oral treatment 2.16.840.1.113883.6.73 2017-01 A01AD01 epinephrine 2.16.840.1.113883.6.73 2017-01 A01AD02 benzydamine 2.16.840.1.113883.6.73 2017-01 A01AD05 acetylsalicylic acid 2.16.840.1.113883.6.73 2017-01 A01AD06 adrenalone 2.16.840.1.113883.6.73 2017-01 A01AD07 amlexanox 2.16.840.1.113883.6.73 2017-01 A01AD08 becaplermin 2.16.840.1.113883.6.73 2017-01 A01AD11 various 2.16.840.1.113883.6.73 2017-01 A02 DRUGS FOR ACID RELATED DISORDERS 2.16.840.1.113883.6.73 2017-01 A02A ANTACIDS 2.16.840.1.113883.6.73 2017-01 A02AA Magnesium compounds 2.16.840.1.113883.6.73 2017-01 A02AA01 magnesium carbonate 2.16.840.1.113883.6.73 2017-01 A02AA02 magnesium oxide 2.16.840.1.113883.6.73 2017-01 A02AA03 magnesium peroxide 2.16.840.1.113883.6.73 2017-01 A02AA04 magnesium hydroxide 2.16.840.1.113883.6.73 2017-01 A02AA05 magnesium silicate 2.16.840.1.113883.6.73 2017-01 A02AA10 combinations 2.16.840.1.113883.6.73 2017-01 A02AB Aluminium compounds 2.16.840.1.113883.6.73 2017-01 A02AB01 aluminium hydroxide 2.16.840.1.113883.6.73 2017-01 A02AB02 algeldrate 2.16.840.1.113883.6.73 2017-01 A02AB03 aluminium phosphate 2.16.840.1.113883.6.73 2017-01 A02AB04 dihydroxialumini sodium carbonate 2.16.840.1.113883.6.73 2017-01 A02AB05 aluminium acetoacetate 2.16.840.1.113883.6.73 2017-01 A02AB06 aloglutamol 2.16.840.1.113883.6.73 2017-01 A02AB07 aluminium glycinate 2.16.840.1.113883.6.73 2017-01 A02AB10 combinations 2.16.840.1.113883.6.73 2017-01 A02AC Calcium compounds 2.16.840.1.113883.6.73 2017-01 A02AC01 calcium carbonate 2.16.840.1.113883.6.73 2017-01 A02AC02 calcium silicate 2.16.840.1.113883.6.73 2017-01 A02AC10 combinations 2.16.840.1.113883.6.73 2017-01 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 2.16.840.1.113883.6.73 2017-01 A02AD01 ordinary salt combinations 2.16.840.1.113883.6.73 2017-01 A02AD02 magaldrate 2.16.840.1.113883.6.73 2017-01 A02AD03 almagate 2.16.840.1.113883.6.73 2017-01 A02AD04 hydrotalcite 2.16.840.1.113883.6.73 2017-01 A02AD05 almasilate 2.16.840.1.113883.6.73 2017-01 A02AF Antacids with antiflatulents © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 5 of 490 MTC epSOSActiveIngredient 2.16.840.1.113883.6.73 2017-01 A02AF01 magaldrate and antiflatulents 2.16.840.1.113883.6.73 2017-01 A02AF02 ordinary salt combinations and antiflatulents 2.16.840.1.113883.6.73 2017-01 A02AG Antacids with antispasmodics 2.16.840.1.113883.6.73 2017-01 A02AH Antacids with sodium bicarbonate 2.16.840.1.113883.6.73 2017-01 A02AX Antacids, other combinations 2.16.840.1.113883.6.73 2017-01 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) 2.16.840.1.113883.6.73 2017-01 A02BA H2-receptor antagonists 2.16.840.1.113883.6.73 2017-01 A02BA01 cimetidine 2.16.840.1.113883.6.73 2017-01 A02BA02 ranitidine 2.16.840.1.113883.6.73 2017-01 A02BA03 famotidine 2.16.840.1.113883.6.73 2017-01 A02BA04 nizatidine 2.16.840.1.113883.6.73 2017-01 A02BA05 niperotidine 2.16.840.1.113883.6.73 2017-01 A02BA06 roxatidine 2.16.840.1.113883.6.73 2017-01 A02BA07 ranitidine bismuth citrate 2.16.840.1.113883.6.73 2017-01 A02BA08 lafutidine 2.16.840.1.113883.6.73 2017-01 A02BA51 cimetidine, combinations 2.16.840.1.113883.6.73 2017-01 A02BA53 famotidine, combinations 2.16.840.1.113883.6.73 2017-01 A02BB Prostaglandins 2.16.840.1.113883.6.73 2017-01 A02BB01 misoprostol 2.16.840.1.113883.6.73 2017-01 A02BB02 enprostil 2.16.840.1.113883.6.73 2017-01 A02BC Proton pump inhibitors 2.16.840.1.113883.6.73 2017-01 A02BC01 omeprazole 2.16.840.1.113883.6.73 2017-01 A02BC02 pantoprazole 2.16.840.1.113883.6.73 2017-01 A02BC03 lansoprazole 2.16.840.1.113883.6.73 2017-01 A02BC04 rabeprazole 2.16.840.1.113883.6.73 2017-01 A02BC05 esomeprazole 2.16.840.1.113883.6.73 2017-01 A02BC06 dexlansoprazole 2.16.840.1.113883.6.73 2017-01 A02BC07 dexrabeprazole 2.16.840.1.113883.6.73 2017-01 A02BC53 lansoprazole, combinations 2.16.840.1.113883.6.73 2017-01 A02BC54 rabeprazole, combinations 2.16.840.1.113883.6.73 2017-01 A02BD Combinations for eradication of Helicobacter pylori 2.16.840.1.113883.6.73 2017-01 A02BD01 omeprazole, amoxicillin and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD02 lansoprazole, tetracycline and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD03 lansoprazole, amoxicillin and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD04 pantoprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD05 omeprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD06 esomeprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD07 lansoprazole, amoxicillin and clarithromycin 2.16.840.1.113883.6.73 2017-01 A02BD08 bismuth subcitrate, tetracycline and metronidazole 2.16.840.1.113883.6.73 2017-01 A02BD09 lansoprazole, clarithromycin and tinidazole 2.16.840.1.113883.6.73 2017-01 A02BD10 lansoprazole, amoxicillin and levofloxacin 2.16.840.1.113883.6.73 2017-01 A02BD11 pantoprazole, amoxicillin, clarithromycin and metronidazole © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 6 of 490 MTC epSOSActiveIngredient 2.16.840.1.113883.6.73 2017-01 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 2.16.840.1.113883.6.73 2017-01 A02BX01 carbenoxolone 2.16.840.1.113883.6.73 2017-01 A02BX02 sucralfate 2.16.840.1.113883.6.73 2017-01 A02BX03 pirenzepine 2.16.840.1.113883.6.73 2017-01 A02BX04 methiosulfonium chloride 2.16.840.1.113883.6.73 2017-01 A02BX05 bismuth subcitrate 2.16.840.1.113883.6.73 2017-01 A02BX06 proglumide 2.16.840.1.113883.6.73 2017-01 A02BX07 gefarnate 2.16.840.1.113883.6.73 2017-01 A02BX08 sulglicotide 2.16.840.1.113883.6.73 2017-01 A02BX09 acetoxolone 2.16.840.1.113883.6.73 2017-01 A02BX10 zolimidine 2.16.840.1.113883.6.73 2017-01 A02BX11 troxipide 2.16.840.1.113883.6.73 2017-01 A02BX12 bismuth subnitrate 2.16.840.1.113883.6.73 2017-01 A02BX13 alginic acid 2.16.840.1.113883.6.73 2017-01 A02BX51 carbenoxolone, combinations excl.
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Automated Annotation of Structurally Uncharacterized Metabolites in Human Metabolomics Studies by Systems Biology Models
    Technische Universität München Automated annotation of structurally uncharacterized metabolites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell 2019 Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt Technische Universität München Lehrstuhl für Experimentelle Bioinformatik Automated annotation of structurally uncharacterized metabo- lites in human metabolomics studies by systems biology models Jan-Dominik Bernd Quell Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Er- nährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzender: Prof. Dr. Dmitrij Frischmann Prüfer der Dissertation: 1. Prof. Dr. Hans-Werner Mewes 2. Prof. Dr. Bernhard Küster Die Dissertation wurde am 28.11.2018 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 28.01.2019 angenommen. „Der Mensch muß bei dem Glauben verharren, daß das Unbegreifliche begreiflich sei; er würde sonst nicht forschen.“ Johann Wolfgang von Goethe i Danksagung Zunächst möchte ich mich ganz besonders bei meinem Doktorvater (Hans-)Werner Mewes bedanken, der mir nicht nur die Möglichkeit gegeben hat an seinem Institut des Helmholtz Zentrums München sowie seinem Lehrstuhl an der Technischen Uni- versität München in Forschung und Lehre zu arbeiten, sondern auch meine Laufbahn
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Title Effects of N-Acetyl-Leucine and Its Enantiomers in Niemann-Pick
    bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title Effects of N-Acetyl-Leucine and its enantiomers in Niemann-Pick disease type C cells Danielle te Vruchte1, Anthony Galione2, Michael Strupp3 and Michiko Mann1 1IntraBio Ltd, Oxford University Begbroke Science Park, Woodstock Road, Oxford, UK 2Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, UK 3Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany Corresponding author Danielle te Vruchte Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Conflicts of Interest A.G. is a cofounder, shareholder and consultant to IntraBio. M.Y-M and D.t.V. are shareholders in IntraBio. M.S. acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion, is a shareholder of IntraBio and Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. M.S. has received speaker’s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Grunenthal, GSK, Henning Pharma, Interacoustics, Merck, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. bioRxiv preprint doi: https://doi.org/10.1101/826222; this version posted October 31, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti Et Al
    US 20170209462A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0209462 A1 Bilotti et al. (43) Pub. Date: Jul. 27, 2017 (54) BTK INHIBITOR COMBINATIONS FOR Publication Classification TREATING MULTIPLE MYELOMA (51) Int. Cl. (71) Applicant: Pharmacyclics LLC, Sunnyvale, CA A 6LX 3/573 (2006.01) A69/20 (2006.01) (US) A6IR 9/00 (2006.01) (72) Inventors: Elizabeth Bilotti, Sunnyvale, CA (US); A69/48 (2006.01) Thorsten Graef, Los Altos Hills, CA A 6LX 3/59 (2006.01) (US) A63L/454 (2006.01) (52) U.S. Cl. CPC .......... A61 K3I/573 (2013.01); A61K 3 1/519 (21) Appl. No.: 15/252,385 (2013.01); A61 K3I/454 (2013.01); A61 K 9/0053 (2013.01); A61K 9/48 (2013.01); A61 K (22) Filed: Aug. 31, 2016 9/20 (2013.01) (57) ABSTRACT Disclosed herein are pharmaceutical combinations, dosing Related U.S. Application Data regimen, and methods of administering a combination of a (60) Provisional application No. 62/212.518, filed on Aug. BTK inhibitor (e.g., ibrutinib), an immunomodulatory agent, 31, 2015. and a steroid for the treatment of a hematologic malignancy. US 2017/0209462 A1 Jul. 27, 2017 BTK INHIBITOR COMBINATIONS FOR Subject in need thereof comprising administering pomalido TREATING MULTIPLE MYELOMA mide, ibrutinib, and dexamethasone, wherein pomalido mide, ibrutinib, and dexamethasone are administered con CROSS-REFERENCE TO RELATED currently, simulataneously, and/or co-administered. APPLICATION 0008. In some aspects, provided herein is a method of treating a hematologic malignancy in a subject in need 0001. This application claims the benefit of U.S.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Theophylline-7-Acetic Acid
    Theophylline-7-acetic acid sc-237085 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Theophylline-7-acetic acid STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH2 HAZARD INSTABILITY0 SUPPLIER Santa Cruz Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060 800.457.3801 or 831.457.3800 EMERGENCY ChemWatch Within the US & Canada: 877-715-9305 Outside the US & Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 SYNONYMS C9-H10-N4-O4, "purine-7-acetic acid, 1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxo-", acefylline, acephylline, 7-(carboxymethyl)theophylline, "1, 2, 3, 6-tetrahydro-1, 3-dimethyl-2, 6-dioxopurine-7-acetic acid", "7-theophyllineacetic acid", "7-theophyllinylacetic acid", alkaloid Section 2 - HAZARDS IDENTIFICATION CHEMWATCH HAZARD RATINGS Min Max Flammability: 1 Toxicity: 2 Body Contact: 2 Min/Nil=0 Low=1 Reactivity: 1 Moderate=2 High=3 Chronic: 2 Extreme=4 1 of 8 CANADIAN WHMIS SYMBOLS EMERGENCY OVERVIEW RISK Harmful if swallowed. Irritating to eyes, respiratory system and skin. POTENTIAL HEALTH EFFECTS ACUTE HEALTH EFFECTS SWALLOWED ! Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual. ! Xanthine derivatives may produce nausea, vomiting, anorexia, stomach pain, vomiting of blood and diarrhea. Protein in the urine, increased amounts of urine output, and increased excretion of renal tubular cells and red blood cells may also occur.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis Et Al
    USOO949854.4B2 (12) United States Patent (10) Patent No.: US 9.498,544 B2 Ennis et al. (45) Date of Patent: Nov. 22, 2016 (54) GENETICALLY MODIFIED HUMAN (56) References Cited UMIBILICAL CORD PERVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR U.S. PATENT DOCUMENTS TREATMENT OF BIOLOGICAL, OR 5,158,867 A 10/1992 McNally et al. CHEMICAL AGENTS 5,919,702 A 7/1999 Purchio et al. 6,132,724 A 10/2000 Blum (71) Applicant: Tissue Regeneration Therapeutics 7,122,178 B1 10/2006 Simmons et al. 7,547,546 B2 6/2009 Davies et al. Inc., Toronto (CA) 2003.0161818 A1 8, 2003 Weiss et al. 2004/O136967 A1 7/2004 Weiss et al. 2004/O137612 A1 7/2004 Baksh et al. (72) Inventors: Jane Elizabeth Ennis, Oakville (CA); 2005/OO 19911 A1 1/2005 Gronthos et al. Jeffrey Donald Turner, 2005, 0148074 A1 7/2005 Davies et al. Chute-a-Blondeau (CA); John Edward 2005/O158289 A1 7/2005 Simmons et al. Davies, Toronto (CA) 2005/0281790 A1 12/2005 Simmons et al. 2006, OOO8452 A1 1/2006 Simmons et al. 2006, O193840 A1 8, 2006 Gronthos et al. (73) Assignee: Tissue Regeneration Therapeutics 2006, O199263 A1 9/2006 Auger et al. Inc., Toronto (CA) 2006/0286O77 A1 12/2006 Gronthos et al. 2007/0134205 A1 6/2007 Rosenberg 2008.0020459 A1 1/2008 Baksh et al. (*) Notice: Subject to any disclaimer, the term of this 2008.0113434 A1 5/2008 Davies et al. patent is extended or adjusted under 35 2009/0047277 A1 2/2009 Reed et al.
    [Show full text]